Drug Profile
ALB 408
Alternative Names: ALB-408Latest Information Update: 29 Aug 2023
Price :
$50
*
At a glance
- Originator Pharis Biotec
- Class Peptides
- Mechanism of Action CXCR4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Asthma; Cancer; HIV infections; Rheumatoid arthritis; Wounds
Most Recent Events
- 29 Aug 2023 Preclinical development is ongoing in Asthma, Cancer, HIV infections, Rheumatoid arthritis and Wounds in Germany (Pharis Biotec pipeline, August 2023)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Asthma in Germany
- 28 Feb 2020 No recent reports of development identified for preclinical development in Cancer in Germany